Endocrinology

Top Story

Nearly 80% respond to novel growth factor for NASH

April 22, 2017

AMSTERDAM — With 12 weeks of treatment, more than one-third of biopsy-diagnosed non-alcoholic steatohepatitis patients who received novel growth factor NGM282 achieved normal liver fat content, according to data at the International Liver Congress.

“There were significant and rapid reductions in multiple markers that are relevant to the resolution of NASH and improvement in fibrosis, although more work needs to be done to define this histopathologically,” Stephen A. Harrison, MD, medical director at Pinnacle Clinical Research and visiting professor of hepatology at the Radcliffe Department of Medicine at University of Oxford, U.K., said during his late breaker presentation. “The data strongly support continued development in non-alcoholic steatohepatitis.”

Prader-Willi syndrome treatment trial begins enrollment

April 22, 2017
A phase 2a trial for a novel combination drug to treat Prader-Willi syndrome has initiated enrollment, according to a press release from Saniona, a research company…
In the Journals Plus

Maternal type 1 diabetes influences adiponectin, leptin levels in adolescent offspring

April 21, 2017
Adolescent girls born to mothers with type 1 diabetes have lower levels of adiponectin compared with adolescent girls born to mothers without diabetes; maternal disease…
In the Journals Plus

Idiopathic hyperprolactinemia increases anterior pituitary hormone deficiency risk

April 21, 2017
Patients with idiopathic hyperprolactinemia have a higher risk for anterior pituitary hormone deficiency that may require hormone therapy compared with patients with…

Longitudinal study launched to help determine transition from health to disease

April 21, 2017
Verily Life Sciences LLC announced the launch of a 4-year study in partnership with Duke University School of Medicine and Stanford Medicine to gain a better…
More News Headlines »
CME

Practical Lipidology®: Volume 3, Number 2

This activity is supported by an educational grant from Amgen

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing…
More »
Video
Meeting News

VIDEO: Practitioners should define 3 values patients recognize about the practice

March 1, 2017
More »
Featured
The Endocrine Society Annual Meeting

The Endocrine Society Annual Meeting

CME

Improving Bone Strength and Reducing Fracture Risk in Osteoporosis

This activity is supported by an educational grant from Merck & Co., Inc.

Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue leading to reduced…
More »
Current Issues
View the Current Issues
Advertisement
Advertisement